Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054875074> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2054875074 endingPage "A394" @default.
- W2054875074 startingPage "A394" @default.
- W2054875074 abstract "Simeprevir (SMV) is a once-daily (QD), oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of genotype (GT) 1 and GT4 infection. This Phase III, open-label, single-arm study (RESTORE; NCT01567735) evaluated efficacy/safety of SMV with peginterferon-α-2a/ribavirin (PR) in patients with chronic HCV GT4 infection.107 patients were included. Treatment-naïve (n = 35) and prior relapse patients (n = 22) received SMV 150 mg QD + PR (12 weeks), followed by PR alone (12 or 36 weeks, response-guided [HCV RNA <25 IU/ml detectable/undetectable at week 4 and <25 IU/ml undetectable at week 12]). Prior non-responders (partial, n = 10; null, n = 40) received SMV/PR (12 weeks), followed by PR for 36 weeks. The primary endpoint was sustained virologic response 12 weeks after end of treatment (SVR12).Median age: 49.0 years; 28.0% Black/African; 7.5% IL28B CC; 28.8% METAVIR F4. Overall, 65.4% (70/107) of patients achieved SVR12 (82.9% [29/35] treatment-naïve; 86.4% [19/22] prior relapsers; 60.0% [6/10] prior partial responders; 40.0% [16/40] prior null responders). In treatment-naïve and prior relapser patients fulfilling response-guided criteria for 24 weeks of treatment (88.6% [31/35] and 90.9% [20/22]), SVR12 rates were high: 93.5% [29/31] and 95.0% [19/20], respectively. Overall on-treatment failure and relapse rates were 23.4% (25/107) and 14.6% (12/82), respectively. Adverse events (AEs) were mainly grade 1/2; serious AEs were infrequent (4.7%) and considered unrelated to SMV.Efficacy and safety of SMV 150 mg QD for 12 weeks with PR in treatment-naïve or -experienced patients with chronic HCV GT4 infection were in line with previous reports for HCV GT1 infection." @default.
- W2054875074 created "2016-06-24" @default.
- W2054875074 creator A5090347572 @default.
- W2054875074 date "1995-10-01" @default.
- W2054875074 modified "2023-10-14" @default.
- W2054875074 title "CAH HCV related: Evaluation of five years (1990?1995) therapies with alpha ? interferon" @default.
- W2054875074 doi "https://doi.org/10.1016/0270-9139(95)95297-7" @default.
- W2054875074 hasPublicationYear "1995" @default.
- W2054875074 type Work @default.
- W2054875074 sameAs 2054875074 @default.
- W2054875074 citedByCount "0" @default.
- W2054875074 crossrefType "journal-article" @default.
- W2054875074 hasAuthorship W2054875074A5090347572 @default.
- W2054875074 hasConcept C126322002 @default.
- W2054875074 hasConcept C168563851 @default.
- W2054875074 hasConcept C197934379 @default.
- W2054875074 hasConcept C203014093 @default.
- W2054875074 hasConcept C203092338 @default.
- W2054875074 hasConcept C2522874641 @default.
- W2054875074 hasConcept C2776178377 @default.
- W2054875074 hasConcept C2776408679 @default.
- W2054875074 hasConcept C2776455275 @default.
- W2054875074 hasConcept C2778986448 @default.
- W2054875074 hasConcept C2780040827 @default.
- W2054875074 hasConcept C2909179924 @default.
- W2054875074 hasConcept C71924100 @default.
- W2054875074 hasConcept C90924648 @default.
- W2054875074 hasConceptScore W2054875074C126322002 @default.
- W2054875074 hasConceptScore W2054875074C168563851 @default.
- W2054875074 hasConceptScore W2054875074C197934379 @default.
- W2054875074 hasConceptScore W2054875074C203014093 @default.
- W2054875074 hasConceptScore W2054875074C203092338 @default.
- W2054875074 hasConceptScore W2054875074C2522874641 @default.
- W2054875074 hasConceptScore W2054875074C2776178377 @default.
- W2054875074 hasConceptScore W2054875074C2776408679 @default.
- W2054875074 hasConceptScore W2054875074C2776455275 @default.
- W2054875074 hasConceptScore W2054875074C2778986448 @default.
- W2054875074 hasConceptScore W2054875074C2780040827 @default.
- W2054875074 hasConceptScore W2054875074C2909179924 @default.
- W2054875074 hasConceptScore W2054875074C71924100 @default.
- W2054875074 hasConceptScore W2054875074C90924648 @default.
- W2054875074 hasIssue "4" @default.
- W2054875074 hasLocation W20548750741 @default.
- W2054875074 hasOpenAccess W2054875074 @default.
- W2054875074 hasPrimaryLocation W20548750741 @default.
- W2054875074 hasRelatedWork W1911438026 @default.
- W2054875074 hasRelatedWork W2018887507 @default.
- W2054875074 hasRelatedWork W2031380552 @default.
- W2054875074 hasRelatedWork W2050318447 @default.
- W2054875074 hasRelatedWork W2115522028 @default.
- W2054875074 hasRelatedWork W2129767605 @default.
- W2054875074 hasRelatedWork W2229086442 @default.
- W2054875074 hasRelatedWork W2418652184 @default.
- W2054875074 hasRelatedWork W3008532188 @default.
- W2054875074 hasRelatedWork W3148119108 @default.
- W2054875074 hasVolume "22" @default.
- W2054875074 isParatext "false" @default.
- W2054875074 isRetracted "false" @default.
- W2054875074 magId "2054875074" @default.
- W2054875074 workType "article" @default.